These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 12208487

  • 1. Effects of various fibrates on serum alkaline phosphatase activity.
    Ganotakis E, Tsimihodimos V, Bairaktari E, Rizos E, Athyros V, Seferiades C, Elisaf M.
    Atherosclerosis; 2002 Nov; 165(1):187-8. PubMed ID: 12208487
    [No Abstract] [Full Text] [Related]

  • 2. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
    Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L.
    Am J Cardiol; 2003 Oct 01; 92(7):794-7. PubMed ID: 14516878
    [Abstract] [Full Text] [Related]

  • 3. Abnormal lipid profiles on fibrate derivatives.
    McLeod AJ, Warren RJ, Armitage M.
    Lancet; 1996 Jan 27; 347(8996):261. PubMed ID: 8551900
    [No Abstract] [Full Text] [Related]

  • 4. Fibrate-induced increase in blood urea and creatinine.
    Lipscombe J, Bargman JM.
    Nephrol Dial Transplant; 2001 Jul 27; 16(7):1515. PubMed ID: 11427661
    [No Abstract] [Full Text] [Related]

  • 5. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
    Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ.
    Am J Med; 2009 Oct 27; 122(10):962.e1-8. PubMed ID: 19698935
    [Abstract] [Full Text] [Related]

  • 6. Statin-fibrate combinations in patients with combined hyperlipedemia.
    Athyros VG, Papageorgiou AA, Kontopoulos AG.
    Atherosclerosis; 2001 Mar 27; 155(1):263-4. PubMed ID: 11293392
    [No Abstract] [Full Text] [Related]

  • 7. Lipid profiles on fibric-acid derivatives.
    Capps NE.
    Lancet; 1994 Sep 03; 344(8923):684-5. PubMed ID: 7915370
    [No Abstract] [Full Text] [Related]

  • 8. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
    Dick TB, Marples J, Ledermann HM, Whittington J.
    Curr Med Res Opin; 1981 Sep 03; 7(8):489-502. PubMed ID: 7030635
    [No Abstract] [Full Text] [Related]

  • 9. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
    Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D.
    Nephrol Dial Transplant; 2000 Dec 03; 15(12):1993-9. PubMed ID: 11096145
    [Abstract] [Full Text] [Related]

  • 10. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
    Schonfeld G.
    Atherosclerosis; 1994 Dec 03; 111(2):161-74. PubMed ID: 7718018
    [Abstract] [Full Text] [Related]

  • 11. Drug interactions with fibric acids.
    Lozada A, Dujovne CA.
    Pharmacol Ther; 1994 Aug 03; 63(2):163-76. PubMed ID: 7809177
    [Abstract] [Full Text] [Related]

  • 12. Ciprofibrate and lipid profile.
    Chandler HA, Batchelor AJ.
    Lancet; 1994 Jul 09; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract] [Full Text] [Related]

  • 13. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
    Rizos E, Kostoula A, Elisaf M, Mikhailidis DP.
    Angiology; 2002 Jul 09; 53(3):273-7. PubMed ID: 12025914
    [Abstract] [Full Text] [Related]

  • 14. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Mikhailidis DP, Jagroon IA.
    Metabolism; 2001 Nov 09; 50(11):1385-6. PubMed ID: 11715936
    [No Abstract] [Full Text] [Related]

  • 15. Fibrate treatment can increase serum creatinine levels.
    Tsimihodimos V, Kakafika A, Elisaf M.
    Nephrol Dial Transplant; 2001 Jun 09; 16(6):1301. PubMed ID: 11390746
    [No Abstract] [Full Text] [Related]

  • 16. [Does hypothyroidism potentialize muscular toxicity of fibrates?].
    Harlé JR, Toussirot E, Disdier P, Drancourt M, Weiller PJ.
    Rev Med Interne; 1990 Jun 09; 11(4):336. PubMed ID: 2096444
    [No Abstract] [Full Text] [Related]

  • 17. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
    Maiguma T, Fujisaki K, Itoh Y, Makino K, Teshima D, Takahashi-Yanaga F, Sasaguri T, Oishi R.
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar 09; 367(3):289-96. PubMed ID: 12644902
    [Abstract] [Full Text] [Related]

  • 18. Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.
    Masnatta LD, Cuniberti LA, Rey RH, Werba JP.
    J Chromatogr B Biomed Appl; 1996 Dec 13; 687(2):437-42. PubMed ID: 9017468
    [Abstract] [Full Text] [Related]

  • 19. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
    Rizzo M, Berneis K.
    Curr Med Res Opin; 2007 May 13; 23(5):1103-11. PubMed ID: 17519077
    [Abstract] [Full Text] [Related]

  • 20. Effects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of rats.
    Walli AK, Seidel D.
    Res Exp Med (Berl); 1981 May 13; 179(2):153-61. PubMed ID: 7280363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.